MX2020002241A - Anticuerpos anti-tm4sf y métodos de uso de los mismos. - Google Patents
Anticuerpos anti-tm4sf y métodos de uso de los mismos.Info
- Publication number
- MX2020002241A MX2020002241A MX2020002241A MX2020002241A MX2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- antibodies
- tm4sf1
- tm4sf1 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se describen anticuerpos anti-TM4SF1, y sus fragmentos de unión al antígeno, que se unen a un epítopo en el bucle ECL2 de TM4SF1 humano. También se describen métodos de uso de dichos anticuerpos y fragmentos, incluso para la inhibición de la metástasis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762550994P | 2017-08-28 | 2017-08-28 | |
PCT/US2018/048402 WO2019046338A1 (en) | 2017-08-28 | 2018-08-28 | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002241A true MX2020002241A (es) | 2020-09-03 |
Family
ID=65526015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002241A MX2020002241A (es) | 2017-08-28 | 2018-08-28 | Anticuerpos anti-tm4sf y métodos de uso de los mismos. |
Country Status (8)
Country | Link |
---|---|
US (3) | US11208495B2 (es) |
EP (1) | EP3675906A4 (es) |
JP (2) | JP7241080B2 (es) |
CN (1) | CN111565750B (es) |
AU (1) | AU2018323470A1 (es) |
CA (1) | CA3074111A1 (es) |
MX (1) | MX2020002241A (es) |
WO (1) | WO2019046338A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018323470A1 (en) * | 2017-08-28 | 2020-03-19 | Angiex, Inc. | Anti-TM4SF1 antibodies and methods of using same |
AU2019284915A1 (en) * | 2018-06-12 | 2021-01-14 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
CN110734494B (zh) * | 2019-10-30 | 2021-04-30 | 上海市第一人民医院 | 抗tspan8单克隆抗体及其用途 |
WO2021222783A1 (en) * | 2020-05-01 | 2021-11-04 | Angiex, Inc. | Anti-tm4sf1 antibody drug conjugates and methods of using same |
WO2022026915A2 (en) * | 2020-07-31 | 2022-02-03 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
AU2022242927A1 (en) * | 2021-03-26 | 2023-10-05 | Angiex, Inc. | Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same |
CA3213065A1 (en) * | 2021-03-26 | 2022-09-29 | Paul A. JAMINET | Maytansine-antibody conjugates and methods of using same |
JPWO2022255401A1 (es) * | 2021-06-03 | 2022-12-08 | ||
WO2022255843A1 (ko) * | 2021-06-03 | 2022-12-08 | 주식회사 메드팩토 | Tm4sf19 억제제 및 이의 용도 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US20040214872A1 (en) | 2002-09-26 | 2004-10-28 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
CN101952454B (zh) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 |
EP2385114A4 (en) * | 2008-12-25 | 2012-08-08 | Univ Tokyo | CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY |
PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
KR20140059168A (ko) | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 시신경 척수염 치료용 조성물 및 치료 방법 |
CN102590531A (zh) * | 2012-03-24 | 2012-07-18 | 广西壮族自治区肿瘤防治研究所 | 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法 |
MX2016004579A (es) * | 2013-10-10 | 2016-12-09 | Beth Israel Deaconess Medical Ct Inc | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. |
CN105793253B (zh) | 2013-11-22 | 2019-08-23 | 法玛克亚公司 | 自分泌运动因子抑制剂化合物 |
MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
AU2018323470A1 (en) * | 2017-08-28 | 2020-03-19 | Angiex, Inc. | Anti-TM4SF1 antibodies and methods of using same |
-
2018
- 2018-08-28 AU AU2018323470A patent/AU2018323470A1/en active Pending
- 2018-08-28 CA CA3074111A patent/CA3074111A1/en active Pending
- 2018-08-28 MX MX2020002241A patent/MX2020002241A/es unknown
- 2018-08-28 WO PCT/US2018/048402 patent/WO2019046338A1/en unknown
- 2018-08-28 EP EP18849908.1A patent/EP3675906A4/en active Pending
- 2018-08-28 CN CN201880070504.7A patent/CN111565750B/zh active Active
- 2018-08-28 JP JP2020534793A patent/JP7241080B2/ja active Active
- 2018-08-28 US US16/642,995 patent/US11208495B2/en active Active
-
2021
- 2021-11-22 US US17/532,660 patent/US20220267461A1/en active Pending
- 2021-11-22 US US17/532,664 patent/US20220153860A1/en active Pending
-
2023
- 2023-03-06 JP JP2023033463A patent/JP2023071888A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3675906A4 (en) | 2021-05-26 |
CN111565750A (zh) | 2020-08-21 |
JP2020534351A (ja) | 2020-11-26 |
CN111565750B (zh) | 2023-11-03 |
AU2018323470A1 (en) | 2020-03-19 |
JP2023071888A (ja) | 2023-05-23 |
CA3074111A1 (en) | 2019-03-07 |
US20200270360A1 (en) | 2020-08-27 |
EP3675906A1 (en) | 2020-07-08 |
US20220267461A1 (en) | 2022-08-25 |
US20220153860A1 (en) | 2022-05-19 |
WO2019046338A1 (en) | 2019-03-07 |
US11208495B2 (en) | 2021-12-28 |
JP7241080B2 (ja) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002241A (es) | Anticuerpos anti-tm4sf y métodos de uso de los mismos. | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
SG10201901057UA (en) | Anti-pd-l1 antibodies | |
MY186334A (en) | Anti-her2 antibodies and immunoconjugates | |
TN2019000272A1 (en) | Anti-ilt4 antibodies and antigen-binding fragments. | |
PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
PH12016502518A1 (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
SG10201804931QA (en) | Anti-cll-1 antibodies and immunoconjugates | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
SG10201900571YA (en) | Anti-pd-1 antibodies | |
NZ761537A (en) | Anti-human ox40l antibodies, uses & methods | |
MX2022014695A (es) | Anticuerpos anti-gitr y sus usos. | |
MX2020010951A (es) | Anticuerpos anti-hla-g y utilizacion de los mismos. | |
PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
MX2023006416A (es) | Anticuerpos, usos y metodos. | |
PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
EA201692560A1 (ru) | Моноклональные антитела против эпитопа her2 и способы их применения |